Amplia gets nod for new cancer drug trial ahead of US push

The Sydney Morning Herald - Nov 19, 2026

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Read full article

More News

Sign Up Now

Subscribe to us for the latest news from Banking Reporter

Banking Reporter

Banking Reporter is the largest-circulated online business news in the United States, bringing a whole new genre of business journalism more up close and more incisive.